ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Cited by (999)

Items 601–700 of 999

1. Near-infrared targeted EGFR fluorescent probe for tumor imaging and diagnosis
   Wenjing Huang, Li Wang, Hao Zhang, Zhihao Han, Yueqing Gu · 2023 · Sensors and Actuators B Chemical
2. MicroRNA expression analysis in endometriotic serum treated mesenchymal stem cells
   Mazen Abdel Rasheed, Ghada Nour Eldeen, Marwa Mahmoud, Mahmoud ElHefnawi, Nourhan Abu-Shahba, Mohamed Reda, Khaled A. Elsetohy, Michael Nabil, Amr Elnoury, Tamer Taha et al. · 2017 · EXCLI journal
3. Deficiency in the secreted protein Semaphorin3d causes abnormal parathyroid development in mice
   Anamika Singh, Masum M. Mia, Dasan Mary Cibi, Ashutosh Kumar Arya, Sanjay Kumar Bhadada, Manvendra Kumar Singh · 2019 · Journal of Biological Chemistry
4. CARF, As An Oncogene, Promotes Colorectal Cancer Stemness By Activating ERBB Signaling Pathway
   Weiyi Dong, Zheng Cao, Yanmin Pang, Teng Feng, Hongtao Tian · 2019 · OncoTargets and Therapy
5. Epithelium-derived Indian Hedgehog restricts stromal expression of ErbB family members that drive colonic tumor cell proliferation
   B. Florien Westendorp, Olga N. Karpus, Pim J. Koelink, Jacqueline L.M. Vermeulen, Sander Meisner, Jan Köster, Nikè V.J.A. Büller, Manon E. Wildenberg, Vanesa Muncan, Gijs R. VAN DEN BRINK · 2021 · Oncogene
6. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers
   Tianfeng Lan, Xue Xia, Louisa Chard Dunmall, Jinxin Miao, Yaohe Wang · 2021 · Aging
7. Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function
   Nathália Kersting, Bárbara Kunzler Souza, Igor Araújo Vieira, Rafael Pereira dos Santos, Danielly Brufatto Olguins, Lauro José Gregianin, Andre Tesainer Brunetto, Algemir Lunardi Brunetto, Rafael Roesler, Caroline Brunetto de Farias et al. · 2018 · Oncology
8. Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity
   Foteini Bartzoka, Mónica González-Magaldi, Patrick O. Byrne, Nicole I. Callery, Kalina A. Hristova, Daniel J. Leahy · 2022 · Biochemical Journal
9. RSPO3 Furin domain-conjugated liposomes for selective drug delivery to LGR5-high cells
   Peter van Kerkhof, Tomica Kralj, Francesca Spanevello, Louis van Bloois, Ingrid Jordens, Jelte van der Vaart, Cara Jamieson, Alessandra Merenda, Enrico Mastrobattista, Madelon M. Maurice · 2023 · Journal of Controlled Release
10. Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation
    Zhili Zhuo, Dongni Zhang, Wenping Lü, Xiaoqing Wu, Yongjia Cui, Weixuan Zhang, Mengfan Zhang · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
11. Cytotoxic Effects of Plant Secondary Metabolites and Naturally Occurring Bioactive Peptides on Breast Cancer Model Systems: Molecular Mechanisms
    Diana Zasheva, Petko Mladenov, Silvina Zapryanova, Zlatina Gospodinova, Mariyana S. Georgieva, Irina Alexandar, Valentin Velinov, Dimitar L. Djilianov, Daniela Moyankova, Lyudmila Simova‐Stoilova · 2024 · Molecules
12. Semaphorin 3E–Plexin D1 Axis Drives Lung Fibrosis through ErbB2‐Mediated Fibroblast Activation
    Zhesong Deng, Jinkun Chen, Ruonan Yang, Yuan Zhan, Shanshan Chen, Jiaheng Zhang, Hao Fu, Yiya Gu, Qian Huang, Jixing Wu et al. · 2025 · Advanced Science
13. Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
    Shom Goel, Ian E. Krop · 2015 · Journal of Clinical Oncology
14. Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection
    Yao Liu, Qun Y. Zhou, Xiao‐Shun He, Li-Ming Song, Lin Chen, Weijuan Jiao, Tong Shen, Su Yao, Hua Wu, Zhi-Bin Hu et al. · 2015 · Oncotarget
15. Conformation‐Independent QSAR Study on Human Epidermal Growth Factor Receptor‐2 (HER2) Inhibitors
    Pablo R. Duchowicz, Silvina E. Fioressi, Eduardo Alberto Castro, Karolina Wróbel, Nnenna Ekpereka Ibezim, Daniel E. Bacelo · 2017 · ChemistrySelect
16. Radiation‐activated prosurvival signaling pathways in cancer cells
    Michel M. Ouellette, Ying Yan · 2019 · Precision Radiation Oncology
17. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma
    Kelly V. Pinheiro, Amanda Thomaz, Bárbara Kunzler Souza, Victoria Anne Metcalfe, Natália Hogetop Freire, Andre Tesainer Brunetto, Caroline Brunetto de Farias, Mariane da Cunha Jaeger, Victorio Bambini-Júnior, Christopher G. Smith et al. · 2020 · Molecular Biology Reports
18. Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
    Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofía Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero et al. · 2022 · Cell Death and Disease
19. Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
    Anja Wagner, Edgar Galicia‐Andrés, Magdalena Teufl, Lukáš Gold, Christian Obinger, Peter Sykacek, Chris Oostenbrink, Michael W. Traxlmayr · 2022 · Biochemistry
20. Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a ‐f
    Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, Mika Kato Kaneko, Yukinari Kato · 2023 · Cancer Science
21. TMED2 promotes glioma tumorigenesis by being involved in EGFR recycling transport.
    Chang-Ning Sun, Yihan Zhang, Zhuangzhi Wang, Jin Chen, Junhua Zhang, Yu-Chao Gu · 2024 · International Journal of Biological Macromolecules
22. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma
    Alison L. Halpern, Patrick D. Kohtz, Allana M. White, Anna K. Houk, Jacob F. Rehring, Levent Hanson, Martin D. McCarter, Molishree Umesh Joshi, Xianzhong Meng, David A. Fullerton et al. · 2020 · Digestive Diseases and Sciences
23. Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis
    Jian Zhou, Wanchun Wang, Qian Yan, Yingquan Luo · 2019 · Translational Cancer Research
24. Emerging genetic biomarkers in lung adenocarcinoma
    Jawad Barbar, Maria Armach, Mohammad Hassan Hodroj, Sahar Assi, Clara El Nakib, Nathalie Chamseddine, Hazem I. Assi · 2022 · SAGE Open Medicine
25. Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models
    Andrés Martín Toscani, Rocío G. Sampayo, Federico M. Barabas, Federico Fuentes, Marina Simian, Federico Coluccio Leskow · 2017 · PLoS ONE
26. The impact of structural biology in medicine illustrated with four case studies
    Tiancen Hu, Elizabeth R. Sprague, Michelle Fodor, Travis Stams, Kirk Clark, Sandra W. Cowan‐Jacob · 2017 · Journal of Molecular Medicine
27. A genetic variant of miR‐335 binding site in the ERBB4 3′‐UTR is associated with prognosis of ovary cancer
    Ping Wei, Ling Li, Zhihu Zhang, Wei Zhang, Ming Liu, Xiugui Sheng · 2017 · Journal of Cellular Biochemistry
28. Divergent Signaling Pathways May Lead to Convergence in Cancer Therapy - A Review
    Arem Qayum, Syed Mohmad Shah, Shashank Kumar Singh · 2022 · Cellular Physiology and Biochemistry
29. Mitochondria dysfunction in circulating tumor cells
    Chiara Agnoletto, Stefano Volinia · 2022 · Frontiers in Oncology
30. Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs
    Yu‐Ching Chang, Chung‐Ze Wu, Chao‐Wen Cheng, Jin‐Shuen Chen, Li-Chien Chang · 2023 · Pharmaceuticals
31. Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
    Chuan Wang, Rong-Qi Zou, Guozhong He · 2024 · Frontiers in Immunology
32. Transcriptomes of cervical cancer provide novel insights into dysregulated pathways, potential therapeutic targets, and repurposed drugs
    Md Tamzid Hossain Tanim, Sudipta Deb Nath, Sumaiya Farah Khan, Abira Khan, Abu Ashfaqur Sajib · 2024 · Cancer Treatment and Research Communications
33. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
    Edward Zheng, Marcin Włodarczyk, Andrzej Węgiel, Aleksandra Osielczak, Maria Możdżan, Laura Biskup, Agata Grochowska, Maria Wołyniak, Dominik Gajewski, Mateusz Porc et al. · 2024 · Frontiers in Surgery
34. An Anti-EGFR Antibody–Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer
    Anjong Florence Tikum, Nikita W. Henning, Jessica Pougoue Ketchemen, Alireza Doroudi, Hanan Babeker, Fabrice Ngoh Njotu, Emmanuel Nwangele, Alissar Monzer, Bridget M. Gray, Emina Torlakovic et al. · 2025 · Cancer Research
35. The first radiosynthesis of [11C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling
    Min Wang, Mingzhang Gao, Qi‐Huang Zheng · 2014 · Bioorganic & Medicinal Chemistry Letters
36. ErbB4 regulate extracellular dopamine through the p38 MAPK signaling pathway
    Shu-Xia Cao, Chen‐Xi Wen, Rui Sun, Jia‐Xuan Han, Yan-hui Sun, Xin-xin Xu, Xiao-ming Li, Hong Lian · 2021 · Neuroscience Letters
37. Nano-immunotherapeutic strategies for targeted RNA delivery: Emphasizing the role of monocyte/macrophages as nanovehicles to treat glioblastoma multiforme
    Amanda-Lee Ezra Manicum, Saman Sargazi, Sobia Razzaq, Govindarajan Venkat Kumar, Abbas Rahdar, Simge Er Zeybekler, Qurrat Ul Ain, Muhammad Bilal, M. Ali Aboudzadeh · 2022 · Journal of Drug Delivery Science and Technology
38. Highly Multiplexed Single‐Cell In Situ Protein Analysis with Cleavable Fluorescent Antibodies
    Manas Mondal, Renjie Liao, Lu Xiao, Taylor Eno, Jia Guo · 2017 · Angewandte Chemie
39. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
    Giulia Dazio, Samantha Epistolio, Milo Frattini, Piercarlo Saletti · 2022 · Journal of Clinical Medicine
40. The oxidative aging model integrated various risk factors in type 2 diabetes mellitus at system level
    Yao Chen, Lilin Yao, Shuheng Zhao, Mengchu Xu, Siwei Ren, Lu Xie, Lei Liu, Yin Wang · 2023 · Frontiers in Endocrinology
41. Repositioning of receptor tyrosine kinase inhibitors
    Heba Mohamed Mansour, Aiman Saad El-Khatib · 2023 · Elsevier eBooks
42. HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression
    Qiaoni Shi, Fei Huang, Yalong Wang, Huidong Liu, Haiteng Deng, Ye‐Guang Chen · 2024 · The Journal of Cell Biology
43. New potential targets for treatment of Cushing’s disease: epithelial growth factor receptor and cyclin-dependent kinases
    Hidenori Fukuoka · 2015 · Pituitary
44. Septins: Regulators of Protein Stability
    Olga Vagin, David O. Beenhouwer · 2016 · Frontiers in Cell and Developmental Biology
45. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells
    Lei Wang, Smita S. Matkar, Gengchen Xie, Chiying An, Xin He, Xiangchen Kong, Xiuheng Liu, Xianxin Hua · 2017 · Cancer Biology & Therapy
46. Role of Membrane Cholesterol Levels in Activation of Lyn upon Cell Detachment
    Takao Morinaga, Noritaka Yamaguchi, Yuji Nakayama, Masatoshi Tagawa, Naoto Yamaguchi · 2018 · International Journal of Molecular Sciences
47. Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma
    Lauren C.J. Baker, Arti Sikka, Jonathan Mark Price, Jessica K.R. Boult, Elise Y. Lepicard, Gary Box, Yann Jamin, Terry J. Spinks, Gabriela Krämer-Marek, Martin O. Leach et al. · 2018 · Frontiers in Oncology
48. A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy
    Rakesh Kumar, Marc J. van de Vijver, Giampaolo Tortora, Fortunato Ciardiello, Tzipora Goldkorn, Wilson H. Miller, Larry Norton · 2019 · Cancer Research
49. Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma
    Zhen Huang, Sheng-Lin Wang, Hui Chen, Rong-Kai Shen, Xiao-Dong Li, Qingshan Huang, Chaowen Wu, Dan-feng Weng, Jian-Hua Lin · 2019 · Scandinavian Journal of Clinical and Laboratory Investigation
50. TNFa inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFa signaling
    Li Ma, Chunhua She, Qian Shi, Qiang Yin, Xinxin Ji, Yongrong Wang, Yulong Fan, Xinyao Kong, Peng Li, Zengfeng Sun et al. · 2019 · Cancer Biology and Medicine
51. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Laura Díaz-Gil, Fara Brasó‐Maristany, Claudriana Locatelli, Ariana Centa, Balázs Győrffy, Alberto Ocaña, Aleix Prat, Atanasio Pandiella · 2021 · Journal of Experimental & Clinical Cancer Research
52. Antibody–Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non–Small Cell Lung Cancer
    Sun Min Lim, Chang Gon Kim, Byoung Chul Cho · 2022 · Cancer Research
53. IPO7 promotes pancreatic cancer progression via regulating ERBB pathway
    Ming Li, Dongqiang Xu, Yijun Zhan, Shiyun Tan · 2022 · Clinics
54. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling
    Hiba M. Zalloum, Rabab F. Tayyem, Bashaer Abu‐Irmaileh, Yasser Khalil Bustanji, Malek Zihlif, Mohammad Mohammad, Talal A. Aburjai, Mohammad Suleiman Mubarak · 2015 · Journal of Molecular Graphics and Modelling
55. EGFR-directed antibodies increase the risk of severe infection in cancer patients
    Mehmet Altan, Barbara Ann Burtness · 2015 · BMC Medicine
56. Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
    Mahlet Z. Tamirat, Kari J. Kurppa, Klaus Elenius, Mark S. Johnson · 2020 · Journal of Visualized Experiments
57. AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib
    Barbara Buccinnà, Cristina Ramondetti, Marco Piccinini · 2022 · Biochemical Pharmacology
58. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling
    Lei Qiao, Chao Dong, Wenlei Jia, Binlin Ma · 2023 · Cellular Signalling
59. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
    Xiaoshuang Niu, Peiyao Liu, Xin Zhou, Dan Ou, Xiaoshen Wang, Chaosu Hu · 2023 · Translational Oncology
60. Structural insights into the role and targeting of EGFRvIII
    Atrish Bagchi, Steven E. Stayrook, Katerina T. Xenaki, C.A. Starbird, Sofia Doulkeridou, Rachid el Khoulati, Rob C. Roovers, Karl R. Schmitz, Paul M.P. van Bergen en Henegouwen, Kathryn M. Ferguson · 2024 · Structure
61. Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis
    Pao‐Yen Lin, Bing‐Yan Zeng, Chih‐Wei Hsu, Mein‐Woei Suen, Chao‐Ming Hung, Brendon Stubbs, Yen-Wen Chen, Tien‐Yu Chen, Wei‐Te Lei, Jiann-Jy Chen et al. · 2025 · Biomolecules
62. A clinical decision framework for redox-adapted, EMT-high cancers: From ferroptosis resistance to precision therapeutic stratification
    Moon Nyeo Park, Hyun Soo Kim, Sohyun Park, Rony Abdi Syahputra, Domenico Vittorio Delfino, Seong‐Gyu Ko, Bonglee Kim · 2026 · Redox Biology
63. Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo
    Erez M. Bublil, Tomer Cohen, Christopher J. Arnusch, Adi Peleg, Gur Pines, Sara Lavi, Yosef Yarden, Yechiel Shai · 2016 · Biochemistry
64. Protein kinases as therapeutic targets to develop anticancer drugs with natural alkaloids
    Hanlin Ye, Linlin Wang, Li Ma, Максим Йонов, Gan Qiao, Jianlin Huang, Cheng Li, Yuxi Zhang, Xiaohui Yang, Shousong Cao et al. · 2021 · Frontiers in Bioscience-Landmark
65. Differential expression of the circadian clock network correlates with tumour progression in gliomas
    Marina Petković, Müge Yalçın, Oliver Heese, Angela Relógio · 2023 · BMC Medical Genomics
66. Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
    Wenyan Fu, Guangyao Li, Changhai Lei, Kewen Qian, Shuyi Zhang, Jian Zhao, Shi Hu · 2023 · Theranostics
67. Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
    Kristina Breitenecker, Viola Hedrich, Franziska Pupp, Doris Chen, Eva Řezníčková, Gregor Ortmayr, Heidemarie Huber, Gerhard Weber, Lorenz Balcar, Matthias Pinter et al. · 2023 · Frontiers in Oncology
68. Molecular landscape of borderline ovarian tumours: A systematic review
    Paweł Sadłecki, Małgorzata Walentowicz‐Sadlecka · 2024 · Open Medicine
69. Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice
    Anil Philip Kunnath · 2015 · Journal of Nanomedicine & Nanotechnology
70. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine
    Anna Maria Valentini, Elisabetta Cavalcanti, Marianna Di Maggio, Maria Lucia Caruso · 2017 · Applied immunohistochemistry & molecular morphology
71. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response
    Jacob P. Turowec, Esther W.T. Lau, Xiaowei Wang, Kevin R. Brown, Frédéric A. Fellouse, Kamaldeep K. Jawanda, James Pan, Jason Moffat, Sachdev S. Sidhu · 2018 · Journal of Biological Chemistry
72. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
    Liza Cosca Villaruz, Manuel Cobo, Konstantinos Syrigos, Dimitriοs Mavroudis, Wei Yan Zhang, Jong Seok Kim, Mark A. Socinski · 2019 · Lung Cancer
73. Aberrant STAT1 methylation as a non-invasive biomarker in blood of HCV induced hepatocellular carcinoma
    Umaira Zakir, Nadir Naveed Siddiqui, Faizan-Ul-Hassan Naqvi, Rizma Khan · 2021 · Cancer Biomarkers
74. Chanling Gao suppresses colorectal cancer via PI3K /Akt/ mTOR pathway modulation and enhances quality of survival
    Guo Chen, Tingting Tian, Feiqing Wang, Chun‐Shui Pan, Kai Sun, Xiao‐yi Wang, Bing Yang, Zhu Yang, Dongxin Tang, Jing‐yan Han · 2023 · Environmental Toxicology
75. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
    Peter Andrew Kaufman, Hans P. M. W. Wildiers, Gilles Freyer, Margaret M. Kemeny, Anthony Gonçalvès, Guy Jérusalem, Alison Stopeck, Nandagopal S. Vrindavanam, Florence Dalenc, Nuwan Nanayakkara et al. · 2018 · Clinical Breast Cancer
76. QSAR study of human epidermal growth factor receptor (EGFR) inhibitors: conformation-independent models
    Silvina E. Fioressi, Daniel E. Bacelo, Pablo R. Duchowicz · 2019 · Medicinal Chemistry Research
77. Protein kinase C regulates ErbB3 turnover
    Markus Dietrich, Muhammad Salman Malik, Marianne Skeie Rødland, Vibeke Bertelsen, Espen Stang · 2019 · Experimental Cell Research
78. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor
    Yongjian Huang, Jana Ognjenović, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
79. Brusatol Inhibits Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer PC-9 Cells
    Lu-Ming Yang, Wenmin Zhou, Qiaoru Guo, Xinyue Fan, Dong-Yu Huang, Xiaofei Sun, Jie Yuan, Hua Yu, Hubiao Chen, Jianye Zhang · 2022 · World Journal of Traditional Chinese Medicine
80. Synthesis of novel pyrimido[4,5‐b]quinoline derivatives as dual EGFR/HER2 inhibitors as anticancer agents
    Nahla Said M. Ibrahim, Hanan H. Kadry, Ashraf F. Zaher, Khaled Omar Mohamed · 2023 · Archiv der Pharmazie
81. Transmembrane helix interactions regulate oligomerization of the receptor tyrosine kinase EphA2
    Daniel Wirth, Ece Özdemir, William C. Wimley, Elena B. Pasquale, Kalina A. Hristova · 2024 · Journal of Biological Chemistry
82. Redox Signaling in Endosomes Using the Example of EGF Receptors: A Graphical Review
    Maureen Hebchen, Katrin Schröder · 2024 · Antioxidants
83. Personalized approaches to lung cancer treatment: A review of targeted therapies, pharmacogenomics, and combination strategies
    M. Tabrizi Namini, G. Bhagya, Manjari Sharma · 2025 · Aspects of Molecular Medicine
84. EGFR inhibits DNA mismatch repair
    Peggy Hsieh, Alexander H. Pearlman · 2015 · Proceedings of the National Academy of Sciences
85. CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
    Zhenxing Wang, Lanxin Li, Chunhong Chu, Xiangkai Wei, Qian Liu, Rui Wang, Guoliang Zhang, Guangyao Guangyao, Ying Wang, Lei An et al. · 2023 · International Journal of Oncology
86. Mechanism of action of vinegared Cornu Cervi Degelatinatum in suppressing spleen kidney yang deficient ulcerative colitis through NCK2-JNK pathway
    Tianshi Li, Mengqi Shi, Yan Zhao, Zhongmei He, Ying Zong, Weijia Chen, Rui Du · 2024 · Heliyon
87. ERBB2 Amplification in NSCLC: How Many Faces?
    Jin‐Yuan Shih · 2024 · Journal of Thoracic Oncology
88. Prognostic value of oxidative phosphorylation-related genes in hepatocellular carcinoma
    Luzheng Liu, Jiacheng Chen, Fei Ye, Feng-Ran Chu, Chaoluan Rao, Yong Wang, Yanggang Yan, Jincai Wu · 2024 · Discover Oncology
89. Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
    Chong Wu, Xiaoting Liu, Rong Liu, Shiyao Song, Zi‐Fan Zheng, Yilin Zeng, Yong Mei, Jingyang Zhang, Qi-Jia Duan, Run Lin et al. · 2024 · Advanced Science
90. HER2/ERBB2 immunoreactivity in human retinoblastoma
    Gail M. Seigel, Sharad Sharma, Abigail S. Hackam, Dhaval K. Shah · 2015 · Tumor Biology
91. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers
    Arafath Kaja Najumudeen, Itziar M. D. Posada, Benoit Louis Philippe Lectez, Yong Zhou, Sebastian K.-J. Landor, Adyary Fallarero, Pia Maarit Vuorela, John F. Hancock, Daniel Abankwa · 2015 · Biochemistry
92. Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma
    Xian Shao, Qian Lu, Gang Wang, Wei Huang, Linlin Yang, Zhong Chen · 2018 · OncoTargets and Therapy
93. Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics
    Simon Braumann, Stephan Ernst Baldus, Roman Pfister · 2018 · Journal of Thoracic Disease
94. Circulating tumor cells and the metastatic process: the complexity of malignancy
    Tania Di Raimo, Elena De Santis, Luigi Coppola, Mario Rosario D'Andrea, Francesco Angelini · 2018 · Journal of Cancer Metastasis and Treatment
95. Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms
    Evan M. Braunstein, Hang Chen, Felicia Juarez, Fanghan Yang, Lindsay A. Tao, Igor Makhlin, Donna Marie Williams, Shruti Chaturvedi, Aparna Pallavajjala, Theodoros Karantanos et al. · 2021 · Cancers
96. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
    Rafael Roesler, Bárbara Kunzler Souza, Gustavo Rassier Isolan · 2021 · International Journal of Molecular Sciences
97. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies
    Danesh Hassani, Mahmood Jeddi‐Tehrani, Parisa Yousefi, Samaneh Mansouri-Fard, Maryam Mobini, Hengameh Ahmadi Zare, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Fazel Shokri · 2022 · Cancer Chemotherapy and Pharmacology
98. HER2 (ERBB2) alterations in colorectal cancers
    Nika Tavberidze, Wei Zhang · 2022 · Human Pathology Reports
99. Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance
    Gregory Bick, Jasmine Zhang, Elyse E. Lowe, Xiaoting Zhang · 2022 · Cancer Drug Resistance
100. MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3 / AKT axis
     Ermes Candiello, Gigliola Reato, Federica Verginelli, Gennaro Gambardella, Antonio D′Ambrosio, Noemi Calandra, Francesca Orzan, Antonella Iuliano, Raffaella Albano, Francesco Paolo Sassi et al. · 2023 · Molecular Oncology